Bio-Rad Laboratories announced the launch of its new Bio-Plex Pro RBM Human Metabolic and Hormone Assays.
To better understand the relationship between metabolic and cardiovascular conditions, researchers need to study a wide range of disease-associated biomarkers, including gut and pituitary hormones, acute phase proteins, adipokines, nutrient-binding proteins, and growth factors. Because these biomarkers often act in concert, researchers would benefit greatly from the ability to simultaneously measure multiple analytes in a single blood or cell culture sample. The new Bio-Plex Pro RBM Human Metabolic and Hormone Assays were designed to meet this need.
Bio-Plex Pro RBM Human Metabolic and Hormone Assays comprise seven distinct multiplex panels for the detection of 39 analytes, of which 15 are unique to Bio-Rad’s panels. Myriad RBM’s collaboration with Sanofi and the Population Health Research Institute (PHRI) in testing samples from the ORIGIN diabetes clinical trial was instrumental in the selection of markers in these panels.
Benefits of Bio-Plex Pro RBM Assays include:
• Robust performance — validated to meet rigorous analytical standards and manufactured in accordance with GMP guidelines
• Reproducible data — lot-to-lot correlation specification of R2 ≥ 0.9 based on sample testing
• Rapid results — multiplex data in just 3.5 hours through the use of magnetic beads and the fastest assay protocols
Bio-Plex Pro RBM Human Metabolic and Hormone Assays are compatible with the Bio-Plex® 100/200, Bio-Plex 3D, and Bio-Plex® MAGPIX™ Platforms, as well as all other Luminex-based xMAP Instruments and Software.